Canada Markets close in 5 hrs 17 mins

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3257-0.0143 (-4.21%)
As of 10:42AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.3400
Open0.3401
Bid0.3230 x 3200
Ask0.3296 x 800
Day's Range0.3219 - 0.3401
52 Week Range0.2790 - 2.9950
Volume260,237
Avg. Volume3,406,770
Market Cap59.53M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-0.7690
Earnings DateMar. 10, 2022 - Mar. 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • GlobeNewswire

    Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DUBLIN, Ireland and CHICAGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 1,800,000 ordinary shares of Iterum Therapeutics and 500,000 restricted share units

  • Simply Wall St.

    Is Iterum Therapeutics (NASDAQ:ITRM) Weighed On By Its Debt Load?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • GlobeNewswire

    Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer

    DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical developme